接受卡普赛珠单抗治疗的获得性免疫性血栓性血小板减少性紫癜患者的血管性血友病因子检测
本研究纳入11例接受每日卡普赛珠单抗治疗的获得性免疫性血栓性血小板减少性紫癜(iTTP)患者,在治疗前及治疗期间多次检测血管性血友病因子(VWF)抗原、胶原结合活性、多聚体及六种VWF活性试验。结果显示VWF抗原和胶原结合活性均正常或临界正常,治疗后所有患者均出现超大分子量多聚体,VWF活性试验结果正常或降低但取决于试剂和患者。
要点
- 11例iTTP患者接受卡普赛珠单抗治疗,VWF抗原和胶原结合活性均正常或临界正常。
- 治疗后所有患者均检出超大分子量VWF多聚体。
- VWF活性试验结果正常或降低,但因试剂和患者而异,结果无法预测。
核心结论
- 在卡普赛珠单抗治疗的iTTP患者中,VWF活性试验结果正常或降低但取决于试剂和患者,实验室需了解本地试剂的性能,因为结果无法预测。
研究设计与样本
- 本研究为英国开展的观察性研究,纳入11例诊断为iTTP并接受每日卡普赛珠单抗治疗的患者。
- 在卡普赛珠单抗治疗前及治疗期间多次检测发色法因子VIII活性、VWF抗原、胶原结合活性、VWF多聚体及六种VWF活性试验。
主要发现
- 所有患者的VWF抗原和胶原结合活性水平正常或临界正常。
- 治疗后所有患者均存在超大分子量多聚体。
- 治疗期间VWF活性试验结果正常或降低,但取决于试剂和患者。
临床怎么用
- 在卡普赛珠单抗治疗患者需检测VWF活性的不常见情况下,实验室应了解本地试剂的表现,因为结果无法预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired immune thrombotic thrombocytopenic purpura (iTTP) is a rare disease with a poor prognosis if undiagnosed. It is caused by autoantibody production to the von Willebrand factor (VWF) cleaving protease, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Caplacizumab, an immunoglobulin directed to the platelet glycoprotein Ibα receptor of VWF, has been reported to induce quicker resolution of iTTP compared to placebo. The laboratory measurement of VWF activity was significantly reduced in clinical trials of caplacizumab. Several VWF assays are available in the UK and this study investigated whether differences in VWF parameters were present in 11 patients diagnosed with iTTP and treated with daily caplacizumab. Chromogenic factor VIII activity, VWF antigen, collagen binding activity, VWF multimers and six VWF activity assays were measured prior to caplacizumab therapy and on several occasions during treatment. VWF antigen and collagen binding activity levels were normal or borderline normal in all patients. Ultra-large molecular weight multimers were present in all patients following treatment. VWF activity assays were normal or reduced during treatment, but this was reagent and patient dependant. In the unusual scenario of a caplacizumab-treated patient requiring measurement of VWF activity, it is important that laboratories understand how their local reagents perform as results cannot be predicted.
引用
- Bowyer A, Brown P, Hopkins B, et al. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab. Br J Haematol. 2022. PMID: 35262910. doi:10.1111/bjh.18080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。